{
    "clinical_study": {
        "@rank": "88967", 
        "acronym": "GIH", 
        "arm_group": [
            {
                "arm_group_label": "Glargine/Lispro insulin Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "The G/L Arm will include 0.2 unit/kg/day as insulin glargine daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; plus 0.2 unit/kg/day as lispro divided between three meals for all insulin-na\u00efve patients. A \"coverage\" dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent will be divided between 3 meals. The maximum starting \"coverage\" dose will be 0.4 units/kg per day."
            }, 
            {
                "arm_group_label": "Glargine/Lispro/NPH insulin Arm", 
                "arm_group_type": "Experimental", 
                "description": "The G/L/N Protocol will include 0.2 unit/kg/day as insulin glargine daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; plus 0.2 unit/kg/day as lispro divided between three meals for all the insulin-na\u00efve patients. A \"coverage\" dose of 0.1 unit/kg/day of NPH for each 10 mg of prednisone or its equivalent will be given twice daily with the administration of the glucocorticoid. The maximum starting \"coverage\" dose will be 0.4 units/kg per day."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that formula that includes patient weight and glucocorticoid\n      dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who\n      are to be treated with pharmacological doses of glucocorticoids."
        }, 
        "brief_title": "The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hyperglycemia", 
            "Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Hyperglycemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The target fasting and pre-meal FSG will be 90-140 mg/dL, and the random FSG will be less\n      than180 mg/dL, taking into consideration the ADA/AACE target glucose levels in non-ICU\n      patients (15).\n\n      The G/L Protocol will include 0.2 unit/kg/day as insulin glargine once daily if the dose is\n      between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; plus\n      0.2 unit/kg/day as lispro divided between three meals for all insulin-na\u00efve patients. A\n      \"coverage\" dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent\n      will be divided between 3 meals. The maximum starting \"coverage\" dose will be 0.4 units/kg\n      per day.\n\n      The prandial dose of lispro will be increased by 10% if the pre-lunch, pre-dinner, or\n      bedtime FSG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime FSG\n      is >200 mg/dL. The prandial dose of lispro will be decreased by 10% if the pre-lunch,\n      pre-dinner, or bedtime FSG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner\n      or bedtime FSG is less than 70 mg/dL.\n\n      The G/L/N Protocol will include 0.2 unit/kg/day as insulin glargine once daily if the dose\n      is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units;\n      plus 0.2 unit/kg/day as lispro divided between three meals for all the insulin-na\u00efve\n      patients. A \"coverage\" dose of 0.1 unit/kg/day of NPH for each 10 mg of prednisone or its\n      equivalent will be given twice daily with the administration of the glucocorticoid. The\n      maximum starting \"coverage\" dose will be 0.4 units/kg per day.\n\n      The NPH dose will be increased by 10% if the pre-lunch, pre-dinner, or bedtime FSG is\n      between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime FSG is greater\n      than 200 mg/dL. The NPH dose will be decreased by 10% if the pre-lunch, pre-dinner, or\n      bedtime FSG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime FSG\n      is less than 70 mg/dL.\n\n      In both protocols glargine dose will be increased by 10% if the fasting glucose value is\n      141-200 mg/dL and by 20% if the fasting glucose value is more than 200 mg/dL, and decreased\n      by 10% if the fasting FSG is 70-89 mg/dL and by 20% if the fasting FSG is less than 70\n      mg/dL.\n\n      If the patient had an outpatient regimen which includes a total daily dose of insulin (TDI)\n      that exceeds 0.4 unit/kg/day, then the same TDI will be continued with 50% given as glargine\n      once daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or\n      more than 80 units; and 50% given as lispro divided between three meals. The patient will\n      still be randomly assigned to either one of the two protocols as described previously.\n\n      If the patient were on a TDI less than 0.4 unit/kg/day in addition to oral antidiabetic\n      medications as an outpatient, then all the oral antidiabetic medications will be\n      discontinued and the patient will be started on 0.5 unit/kg/day divided as 50% glargine\n      given once daily if the dose is between 40-80 units, or twice daily if the dose is less than\n      40 or more than 80 units; and 50% lispro divided between three meals. The patient will still\n      be randomly assigned to either one of the two protocols based upon even and odd hospital\n      numbers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Admission for COPD exacerbation.\n\n          -  Treatment with pharmacological doses of GC's \u226510 mg of prednisone or its equivalent\n             if they are not on maintenance dose of GC's in the outpatient settings.\n\n          -  Treatment with pharmacological doses of GC's \u226510 mg of prednisone or its equivalent\n             above their maintenance dose of GC's in the outpatient settings.\n\n          -  Have either a previous diagnosis of diabetes mellitus which has been treated with\n             diet or medications, hemoglobin A1c \u22656.5%, or confirmed inpatient hyperglycemia\n             defined as a fasting laboratory glucose or finger stick reading \u2265126 mg/dL or random\n             glucose reading \u2265200 mg/dL on two or more determinations.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810952", 
            "org_study_id": "H-27172"
        }, 
        "intervention": [
            {
                "arm_group_label": "Glargine/Lispro insulin Arm", 
                "description": "In both protocols glargine dose will be increased by 10% if the fasting glucose value is 141-200 mg/dL and by 20% if the fasting glucose value is more than 200 mg/dL, and decreased by 10% if the fasting FSG is 70-89 mg/dL and by 20% if the fasting FSG is less than 70 mg/dL.\nIf the patient had an outpatient regimen which includes a total daily dose of insulin (TDI) that exceeds 0.4 unit/kg/day, then the same TDI will be continued with 50% given as glargine once daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; and 50% given as lispro divided between three meals. The patient will still be randomly assigned to either one of the two protocols as described previously.", 
                "intervention_name": "Active Comparator: Glargine/Lispro insulin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "glargine insulin", 
                    "lispro insulin"
                ]
            }, 
            {
                "arm_group_label": "Glargine/Lispro/NPH insulin Arm", 
                "description": "The G/L/N Protocol will include 0.2 unit/kg/day as insulin glargine daily if the dose is between 40-80 units, or twice daily if the dose is less than 40 or more than 80 units; plus 0.2 unit/kg/day as lispro divided between three meals for all the insulin-na\u00efve patients. A \"coverage\" dose of 0.1 unit/kg/day of NPH for each 10 mg of prednisone or its equivalent will be given twice daily with the administration of the glucocorticoid. The maximum starting \"coverage\" dose will be 0.4 units/kg per day.", 
                "intervention_name": "Glargine/Lispro/NPH insulin arm", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Glargine insulin", 
                    "Lispro insulin", 
                    "NPH insulin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucocorticoids", 
                "Insulin LISPRO", 
                "Glargine", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "glucocorticoids", 
            "hyperglycemia", 
            "diabetes mellitus"
        ], 
        "lastchanged_date": "March 12, 2013", 
        "location": {
            "contact": {
                "email": "glennc@bcm.edu", 
                "last_name": "Glenn R Cunningham, MD", 
                "phone": "832-355-7208"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "St. Luke's Episcopal Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Glenn R Cunningham, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Shadi Abdelnour, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Diana Engineer, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients", 
        "other_outcome": [
            {
                "description": "Determine the total daily dose of insulin required based on weight and GC dosage to achieve average daily finger stick glucose (FSG) levels of 90-140 mg/dL", 
                "measure": "The management of glucocorticoid-induced hyperglycemia in hospitalized patients.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "Assess the usefulness of HbA1c, BMI, fasting glucose or duration of diabetes (if present) as independent predictors of glycemic control.", 
                "measure": "The management of glucocorticoid-induced hyperglycemia in hospitalized patients.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "overall_contact": {
            "email": "glennc@bcm.edu", 
            "last_name": "Glenn R Cunningham, MD", 
            "phone": "832-355-7208"
        }, 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "Glenn R Cunningham, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Average daily glucose levels in patients treated with glargine and lispro (G/L) versus glargine, lispro and NPH (G/L/N) on days 2-5 after the initiation of the treatment protocol.", 
            "safety_issue": "No", 
            "time_frame": "up to 2 years"
        }, 
        "reference": [
            {
                "PMID": "19454391", 
                "citation": "Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009 Jul-Aug;15(5):469-74. Review."
            }, 
            {
                "PMID": "19429873", 
                "citation": "Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009 Jun;32(6):1119-31. doi: 10.2337/dc09-9029. Epub 2009 May 8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810952"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Baylor College of Medicine", 
            "investigator_full_name": "Glenn R. Cunningham", 
            "investigator_title": "Professor of Medicine and Molecular & Cellular Biology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The incidence of hyperglycemia (mean daily FSG >180 mg/dL) with the two regimens.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "The incidence of hypoglycemia (FSG < 70 mg/dL) with the two regimens.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Baylor College of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor College of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}